Zak Mir takes a technical analysis look at some of the most followed small caps on the London market. Today’s selection includes African Pioneer, Boston, BATM, Cora, East Imperial, Emmerson,
Tiziana Life Sciences plc (TILS.L) TiLS files scheme for a corporate reorganisation
London/New York, August 20, 2021 – Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS) (“Old Tiziana”) a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases
Tiziana Life Science (TILS.L) Article Publication on Foralumab in COVID Patients
Tiziana Announces Publication of a Peer Reviewed Article on Data from the Clinical Trial with Intranasally Administered Foralumab, Its Proprietary Fully Human Anti-CD3 Monoclonal Antibody, in Mild to Moderate COVID-19
Traders Cafe with Zak Mir: Bulletin Board Heroes, Friday 13th August 2021 via Vox Markets
Zak Mir takes a charting look at some of the most followed stocks on the London market. Today’s selection includes Advance Energy, Braveheart, Boston, Babcock, Chaarat, Cora, Powerhouse, Premier African,
Tiziana Life Science (Nasdaq: TLSA) ADS Ex-Dividend Date Scheduled for July, 09 2021
THIS ANNOUNCEMENT IS FOR US ADS HOLDERS ONLY
Tiziana Life Sciences plc (TILS.L) Distribution Dates for shares and ADRs in Accustem
Distribution Dates for shares and ADRs in Accustem Sciences Limited
Tiziana Life Sci PLC (TILS.L) P2 Trial with foralumab on Severe COVID19 Patients
NEW YORK & LONDON, June 23, 2021 – Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS), (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, neurology,
Tiziana Life Sci PLC (TILS.L) Appointment of VP of Regulatory Affairs
Tiziana Appoints Dr. Kevin Schutz as Vice-President of Regulatory Affairs
Tiziana Life Sci PLC (TILS.L) Tiziana Applies for Grant from UK-CTAP
Tiziana Responds to UK Call for Development of Innovative ‘Take Home’ Treatments for COVID-19 Disease
Tiziana Life Sci PLC (TILS.L) Significant Immunomodulation effects on Biomarkers
Tiziana Reports Data Indicating Significant Immunomodulation effects on Immune and Inflammatory Biomarkers with Nasally Administered Foralumab in Healthy Volunteers.
Tiziana Life Sci PLC (TILS.L) Significant Immunomodulation effects on Biomarkers
Tiziana Reports Data Indicating Significant Immunomodulation effects on Immune and Inflammatory Biomarkers with Nasally Administered Foralumab in Healthy Volunteers.
Tiziana Life Sci PLC (TILS.L) Trial Initiation in a SPMS Patient with Foralumab
Tiziana Life Sciences Announces Initiation of Clinical Trial in a Secondary Progressive Multiple Sclerosis (SPMS) Patient with Nasal Administration of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, Under an Individual